Amgen, Novartis, Banner Institute Discontinue Alzheimer's Prevention Clinical Research Program
12 July 2019 - 7:30AM
Dow Jones News
By Stephen Nakrosis
Amgen Inc. said Thursday a clinical research program it was
conducting into Alzheimer's prevention with Novartis AG (NVS) and
the Banner Alzheimer's Institute was being discontinued.
The program was studying the effect of the BACE1 inhibitor
CNP520, or umibecestat, as part of the Alzheimer's Prevention
Initiative Generation Program, Amgen said. Specifically, the
program was researching the safety and efficacy of CNP520 for the
prevention or delay of the onset of Alzheimer's disease in certain
patients.
Amgen said "After review of clinical data, the sponsors
concluded that the potential benefit for participants in the
studies did not outweigh the risk."
Amgen and Novartis formed a global collaboration in 2015 to
develop and commercialize pioneering treatments in the field of
migraine and Alzheimer's disease. The studies are sponsored by
Amgen and Novartis, in collaboration with Banner Alzheimer's
Institute, Amgen said.
David Reese, executive vice president of Research and
Development at Amgen, said "Although the outcomes of the research
program did not lead to the results we aimed for, we are committed
to sharing our findings to help advance the medical and scientific
community one step further toward finding a prevention for this
devastating disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 11, 2019 17:15 ET (21:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024